parallel randomized trial

S003051

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Type 2 diabetes (adults)Metabolic dysfunction associated steatotic liver disease or steatohepatitisS003051

Design

Randomized: 128
Start year: 2019
Treatment: 24 weeks, follow-up 24 weeks
Countries: China
Sponsor: (non industry)
Eligibility: type 2 diabetes with HbA1c below 8% and NAFLD, no heavy alcohol use

Conduct and analysis

Blinding: double blind
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Standard care or no added treatment Group A metformin	metformin 500 mg twice daily initial dose; low salt low fat diet and exercise; lifestyle: standard	64	64
A2	Exenatide 5 ug subcutaneous twice daily Group B (exenatide plus metformin)	metformin, initial 500 mg twice daily; lifestyle: standard	64	64

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Standard care or no added treatment A1	Exenatide 5 ug subcutaneous twice daily A2
age	mean (years)	55.56	25.86
age	sd (years)	6.03	6.29
bmi	max (kg/m2)	34.07	35.05
bmi	mean (kg/m2)	25.41	25.44
bmi	min (kg/m2)	20.39	20.33
bmi	sd (kg/m2)	2.32	2.47
female	n	27	25
female	percent	42.19	39.06